CTT...irgendwo wird immer eine Aktie zuerst entdeckt: - 500 Beiträge pro Seite

[circuit]

CTT (860736)

In Deutschland in keinem Board, keinem Aktienbrief bisher erwähnt.

Selbst in den Staaten in einem Monat nur eine halbe Seite voll mit postings.

Aber es könnte sich bald etwas tun. Geheimnisvolle ( Insider?-)käufe die letzten Tage zu fast jedem Preis.

Kurs 3,10 $

Meinungen dazu ?

Letzte news:

COMPETITIVE TECHNOLOGIES` LICENSEES SHOW PROGRESS ON SUNLESS TANNING AND SEXUAL DYSFUNCTION TECHNOLOGIES


Fairfield, CT - (November 4, 2003) - Competitive Technologies, Inc. (AMEX: CTT) announced today that licensees EpiTan Limited (ASX: EPT) and Palatin Technologies, Inc. (AMEX: PTN) have both presented successful Phase IIb results of clinical trials for applications of synthetic analogues of alpha-MSH (alpha-melanocyte-stimulating hormone), a natural hormone secreted by the pituitary gland. A team of researchers at CTT`s client, the University of Arizona (UA) invented the analogue technology.

"We are pleased to see the progress shown on the diverse applications of our client`s technology," said John B. Nano, CTT`s President and CEO. "These are examples of a CTT licensed technology fulfilling needs of attractive global markets in excess of $1 billion."

Mr. Nano continued, "CTT is actively marketing and commercializing several new technologies, including bone biomaterial, wound sealant, language-mastering software, silicon carbide wafer testing, pollution abatement, insulated concrete forms, and automotive safety sensors. We are also continuing to maximize the value of our existing portfolio of technologies to strengthen shareholder value. Our new team has signed seven new revenue generating agreements in the past three months."

Sunless Tanning:

Melbourne, Australia-based EPT (www.epitan.com.au) announced results in its recently completed Phase IIb "sunburn injury" clinical trial. The technology stimulates certain skin cells that produce a dark pigment causing general darkening of the skin. CTT licensed the sunless tanning application of the UA technology exclusively to privately held Melanotan Corporation. CTT owns approximately 22% of Melanotan, which exclusively sub-licensed worldwide rights to the technology to EPT. Melanotan owns 15.2 million shares of EPT, currently trading at A$0.74.

The sunscreen market, $400 million annually in the U.S. alone, is the target audience for products that evolve from this technology. CTT and UA will receive royalties through Melanotan on sales of sunless tanning products developed by EPT. In addition, CTT expects to benefit from its equity ownership in Melanotan.

Sexual Dysfunction:

PTN (www.palatin.com) presented positive safety and efficacy data from its Phase IIb "at home" study of PT-141 for male sexual dysfunction. The nasally administered treatment acts on receptors in the brain to stimulate natural sexual arousal without acting directly on the vascular system. PTN is the exclusive CTT licensee for this important use of the synthetic analogue. PTN used the licensed underlying technology in developing PT-141, an investigational treatment for male and female sexual dysfunction.

An estimated 150 million men worldwide suffer from erectile dysfunction (ED), with some degree of ED affecting half of all men over the age of 40. Revenues generated from the sale of any PTN products using CTT technologies will produce royalties for CTT and its client, the University of Arizona.

PTN announced that the study showed that men with ED taking the intranasally administered drug reported consistently improved erectile function across all dosing levels. The 271 participants were confirmed by patient history to be responsive to sildenafil (Viagraâ). Results of the study showed that the participants who received PT-141 showed improved clinical and statistical erectile function.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The company estimates the global market opportunity for technology transfer services at $150 billion annually. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.

Statements about the Company`s future expectations, including development and regulatory plans, and all other statements in this document other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws and are not guarantees of future performance. These statements involve risks and uncertainties, including those set forth in Item 1 of the Company`s most recent Form 10-K and in CTT`s other filings with the SEC, and are subject to change at any time. The Company`s actual results could differ materially from these forward-looking statements. The Company undertakes no obligation to update publicly any forward-looking statement.

[proFEiT]

was machen die (auf deutsch)?

[circuit]

....umfangreicher Technologietransfer.....in einem 150 Milliarden Markt:

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The company estimates the global market opportunity for technology transfer services at $150 billion annually. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.

[circuit]

Nachbörslich noch folgende Meldung, die vielleicht auch der Grund für die Kursanstiege ist:


Effective October 30, 2003, Competitive Technologies, Inc. (CTT) sold to LawFinance Group, Inc. (LFG) a second portion of its expected $6,000,000 patent infringement judgment against American Cyanamid Company (Defendant) in the MaternaTM lawsuit. On October 31, 2003, CTT received $900,000 cash in exchange for the Assigned Portion (plus court awarded interest from October 31, 2003) of CTT`s share of the potential award.

CTT will include this $900,000 in revenue in its first quarter of fiscal 2004.

In management`s opinion, it is most likely that the Assigned Portion will be $1,125,000, in which case the remaining anticipated proceeds from this expected award would be $3,585,000 in addition to the $1,500,000 already received.

According to the Side Letter Addendum (see Exhibit 10.1), the Assigned Portion will be:

a) $1,125,000 if, in the current Appeal, Defendant does not file a petition for certiorari with the United States Supreme Court (Supreme Court) or the Supreme Court denies Defendant`s petition for certiorari during the current 2003-2004 Term and LFG receives full payment within 7 days of CTT`s receiving payment from Defendant, or

b) $2,160,000 if, in the current Appeal, Defendant files a petition for certiorari with the Supreme Court and the Supreme Court grants Defendant`s petition and LFG receives full payment within 7 days of CTT`s receiving payment from Defendant, or

c) $1,400,000 in any circumstance that does not meet the conditions of a) or b).

CTT retains the remaining anticipated a) $3,585,000, b) $2,550,000, or c) $3,310,000 proceeds from this expected award in addition to the $1,500,000 already received. (On May 19, 2003, CTT received $600,000 cash in exchange for $1,290,000 (plus court awarded interest from May 19, 2003) of CTT`s share of the potential award.)

CTT has no financial obligation to repay LawFinance or to return any portion of the total $1,500,000 received from LawFinance. If CTT`s share of the potential award is less than the total amount sold to LawFinance, the entire amount would be paid to LawFinance and LawFinance would be deemed paid in full. CTT granted LawFinance a security interest in CTT`s share of the potential award.

[circuit]

Die Zahlungen werden also demnächst fließen:

Competitive Technologies` Client Prevails in $54 Million Materna Case
Wednesday November 12, 2:30 pm ET


FAIRFIELD, Conn., Nov. 12 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) announced that the US Court of Appeals for the Federal Circuit (CAFC) has denied Wyeth`s (NYSE: WYE - News) application for rehearing/rehearing en banc of the CAFC September 3, 2003 decision affirming the decision of the US District Court for the District of Colorado (USDC). On August 13, 2002 US Senior District Court Judge John Kane of USDC found in favor of CTT`s client, the University of Colorado, and against Wyeth for an approximate $54 million patent infringement judgment for fraud and unjust enrichment. CTT expects to receive approximately $5.9 million from the award of the net proceeds recovered from Wyeth in this $54 million award, including interest and $1.5 million already received from assignment of portions of the award to LawFinance Group, Inc.
"CTT and its clients have now prevailed in five venues before multiple judges," said John B. Nano, President and CEO of CTT. "We applaud CAFC`s decision to again affirm the lower court`s decision. This ten-year-old case needs to come to closure quickly."

Mr. Nano continued, "CTT continues to achieve profitable growth. Our new team has signed seven revenue-generating agreements in the past three months. We are building an excellent reputation and forming strong customer and client relationships. Our successful global track record is supported by strong technological expertise. We are aggressively marketing and commercializing recently acquired technologies, including bone biomaterial, wound sealant, language-mastering software, silicon carbide wafer testing, pollution abatement, insulted concrete forms and automotive safety sensors."

The litigation involves a prenatal vitamin supplement marketed by Wyeth`s American Cyanamid unit under the Materna(TM) name. A preliminary opinion issued in July 2000 found that Drs. Robert H. Allen and Paul A. Seligman, at CTT`s client, the University of Colorado, are the sole inventors of the improved formulation of the prenatal vitamin supplement, and that American Cyanamid had committed fraud and was unjustly enriched. The litigation began in 1993 for royalties on product sales between 1984 and 1994.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The global market for technology transfer services is estimated at $150 billion annually. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT`s website: http://www.competitivetech.net

[circuit]

War das schon die die technische Reaktion ?

Waren das alles an Gewinnmitnahmen ?

Sehr stabil !

[circuit]

Unsere CTT wird nun so langsam auch von anderen entdeckt.

Siehe obigen Kursverlauf.

Wehe wenn die "Entdecker" noch mehr werden ........

;-))

[circuit]

....da kommen sie ja ( + 15 % )

[circuit]

Warum so "viel" Umsatz heute in Deutschland ?

Gab es irgendwelche Empfehlungen ?

[dehoim]

Insider

AKTIONÄR GIBT SICH DIE EHRE

dehoim

[circuit]

So, nachdem "unsere" Entdeckung entdeckt wurde, kann jeder seine Entscheidung daraus ableiten.

Hat Spaß gemacht.

Gruß

circuit

[circuit]

Da war meine "Verkaufsempfehlung" wohl doch zum richtigen Zeitpunkt.

Wenn sich diese Sache noch eine Weile hinauszögert, kann es eng werden....

Wyeth Appeals 10-Year Old Materna Litigation to Supreme Court
Thursday February 12, 9:03 am ET


FAIRFIELD, Conn., Feb. 12 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) announced that it has been advised that Wyeth (NYSE: WYE - News) has filed an appeal to the Supreme Court of the United States on the $58.2 million patent infringement judgment for fraud and unjust enrichment against Wyeth, and in favor of CTT`s client, the University of Colorado.
On November 12, 2003, the US Court of Appeals for the Federal Circuit denied a rehearing/rehearing en banc for this case of the Court`s September 3, 2003 affirmation of the August 13, 2002 decision of US Senior District Court Judge John Kane of the US District Court for the District of Colorado. A preliminary opinion issued in July 2000 found that Drs. Robert H. Allen and Paul A. Seligman at the University of Colorado, a CTT client, are the sole inventors of the improved formulation of the prenatal vitamin supplement, and that Wyeth had committed fraud and was unjustly enriched.

John B. Nano, President and CEO of CTT said, "We fully anticipate that the highest court in the nation will not hear a case already decided by multiple decisions of the lower courts and will continue to find in favor of the University et al to finally close this litigation which began in 1993 for product sales between 1984 and 1994. Wyeth seems to be unfairly determined to delay the resolution of the case after more than ten years."

Mr. Nano continued, "We had expected that in proper use of the judicial process and a sense of fairness to the University, the citizens of Colorado, and the doctors, that Wyeth would not continue to appeal these judgments against their position. SEC filings indicate that Wyeth accrued a litigation reserve of nearly $17 billion over the last several years. According to court filings they are involved in over 25,000 court cases."

The litigation involves a prenatal vitamin supplement marketed by Wyeth under the Materna(TM) name. The US District Court for the District of Colorado and the US Court of Appeals for the Federal Circuit found that Wyeth had committed fraud for unjust enrichment.

[circuit]

+ 20 %.....die Konsolidierung scheint beendet zu sein.

Die Nachrichtenlage wesentlich verbessert:

Competitive Technologies Reports Profits for Third Quarter Fiscal 2004
Thursday June 10, 8:23 am ET


FAIRFIELD, Conn., June 10 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) today announced profitable results for the three and nine months ended April 30, 2004.
ADVERTISEMENT


CTT`s net income for the first nine months of fiscal 2004 was $3.1 million, compared with a net loss for the first nine months of fiscal 2003 of $1.2 million, an improvement of $4.3 million. The profitable business results have increased shareholders` equity to $4.9 million. The net income of $2.7 million for the third quarter of fiscal 2004 compared to a net loss of $0.5 million in the third quarter of fiscal 2003, an improvement of $3.2 million.

Revenues for the first nine months of fiscal 2004 increased 236% to $6.3 million compared with $1.9 million for the first nine months of fiscal 2003. Revenues for the third quarter of fiscal 2004 increased 516% to $4.1 million from $0.7 million in the third quarter of fiscal 2003. Revenues for the third quarter of fiscal 2004 include $3.5 million from the resolution of the Materna(TM) litigation that became final and unappealable in April 2004. Revenues in previous quarters of fiscal 2004 included $1.2 million from sales of portions of proceeds from this litigation.

"Earlier this week, subsequent to the third quarter, CTT received a favorable ruling from the US Court of Appeals for the Federal Circuit in the LabCorp litigation," said John B. Nano, CTT`s President and CEO. "As a result of this decision, we expect to generate significant revenues from new homocysteine assay licenses. About 20 million assays are performed annually, and this number is increasing substantially each year. Additionally, CTT`s business development team is aggressively marketing and successfully growing our technology portfolio. During this quarter a patented technology from our client, Lehigh University, was officially included in the revenue-generating MPEG-4 Visual Patent License Program pool. An independent market research group has projected approximately 500 million products per year utilizing MPEG-4 technology by 2008. In May 2004, the Korean Technology Transfer Center (KTTC) sponsored a technology forum at the COEX Center in Seoul exclusively for CTT to present technologies selected for the Korean market. The objective of our alliance with KTTC is to assist companies in our respective markets with commercialization of technologies. This successful program has resulted in a high level of interest in CTT technologies from several companies, including global leaders such as Samsung, LG and Hyundai."

Mr. Nano continued, "With three successive profitable quarters, we expect to achieve our business plan objective of profitability for 2004. Our balance sheet at the end of the quarter was strong. We are marketing a wide range of highly appealing innovative technologies. In this quarter we added a patented anti-cancer / anti-angiogenesis technology from the University of South Carolina Research Foundation to our portfolio. It joins a strong group of commercially viable technologies including nanotechnology bone biomaterial, wound sealant, an enterovirus assay, language-mastering software, silicon carbide wafer testing, fuel additives, specialty chemicals, and pollution abatement. We are aggressively pursuing new license agreements, structuring payment obligations contingent upon revenues, and collecting amounts previously considered uncollectible. We are continuing to improve our results to build shareholder value, creating solid relationships with customers and clients in the US and abroad, forming strategic alliances that allow us to extend our reach, and expanding the scope of our portfolio to satisfy commercial needs."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The global market for technology transfer services is estimated at $150 billion annually. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT`s website: http://www.competitivetech.net

[tecdaexchen]

http://www.finanznachrichten.de/goto.asp?id=3500862

[circuit]

und weitere Prozente:

[circuit]

Nach der Konsolidierung darf wieder ein Augenmerk auf CT gerichtet werden. Vor allem nach diesen news. Weniger wichtig ist die 1 Mio. Interessanter sind die zu erwartenden Folgeeinnahmen von allen Laboratorien !

Competitive Technologies Wins Homocysteine Case
Thursday August 5, 4:18 pm ET


FAIRFIELD, Conn., Aug. 5 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) announced today that the US Court of Appeals for the Federal Circuit (CAFC) ruled in favor of CTT and its clients against Laboratory Corporation of America Holdings` (LabCorp) (NYSE: LH - News). The CAFC has denied LabCorp`s petition for a rehearing or rehearing en banc win of the homocysteine assay patent infringement case. On June 8, 2004 the CAFC had affirmed the August 2003 decision of the U.S. District Court for the District of Colorado (CDC) in favor of CTT and its clients against LabCorp.
Pursuant to the CDC order and judgment, CTT, the University of Colorado and Columbia University had been awarded $2.1, and CTT`s licensee, Metabolite Laboratories, Inc. was awarded $4.5 million in damages and interest in this five-year-old case. CTT expects to receive approximately $1 million of the total award. LabCorp previously posted a $6.6 million bond to stay execution of the monetary judgment by the CDC and to stay a permanent injunction from performing homocysteine assays.

CTT and its clients have been receiving a 6% royalty on current homocysteine assays conducted by LabCorp under CTT`s patent rights as a result of a December 2002 CDC-directed agreement. In a separate case that has not been finalized, CTT and its clients also filed for attorney fees and court costs. The assay patent is derived from discoveries made by CTT`s clients, Drs. Robert Allen and Sally Stabler from the University of Colorado and the late Dr. John Lindenbaum from Columbia University.

"CTT and its clients have successfully prevailed in multiple venues in this important case," said John B. Nano, CTT`s President and CEO. "We applaud CAFC`s decision to reaffirm the lower court`s decision and will work with LabCorp for a final licensing agreement."

Mr. Nano continued, "A part of CTT`s strategy of turning technology solutions into commercial dollars is the responsibility to protect the intellectual property of its clients, its licensees and its shareholders. We will continue our active program of collecting from patent infringers all previously withheld royalties from all laboratories conducting homocysteine assays. We estimate that there will be over 20 million homocysteine assays conducted in 2004."

[circuit]

Nun....es war wohl ein längerer Augenblick:

[tupper]

Vielleicht hält dafür auch der Aufwärtstrend länger an!

[circuit]

Da einigen sich 20 Milliarden ( Bayer ) mit lächerlichen 26 Millionen ( Marktkap. CTT )....und andere werden folgen:

25.10.2004 - 16:32 Uhr
Bayer einigt sich im Patentstreit mit Competitive Technologies

DÜSSELDORF (Dow Jones-VWD)--Die Bayer HealthCare LLC, eine Tochter der Bayer AG, Leverkusen, und die Competitive Technologies Inc, Fairfield, haben einen Patentstreit außergerichtlich beigelegt. In dem Streit ging es um einen Test, der auf einer Diagnosemaschine von Bayer eingesetzt wird, um einen Risikofaktor für Herz-Kreislauf-Krankheiten zu bestimmen. Bayer erhält für den Test eine Vermarktungslizenz und wird dafür Lizenzgebühren zahlen, wie Competitive Technologies am Montag mitteilte.
(ENDE) Dow Jones Newswires/25.10.2004/rib/bb

[tupper]

Läuft doch super!
Hast du dir das Jahresergebnis und die Meldung mit Epitan schon angesehen?

[circuit]

Schau Mal da....in welchen Technologien die involviert sind:

www.competitivetech.net/CTT%20Corporate%20Fact%20Sheet%2010-14-04.pdf

[tupper]

http://www.competitivetech.net/LifeDigitalNanoPhys.htm
Ich hoffe, der funzt besser!
CTT scheint tatsächlich nachhaltig den Turnaround zu schaffen. Natürlich enthält die Bilanz eine Reihe von Sondereinnahmen, aber die dürften immer wieder einmal anfallen. Das Portfolio ist hochinteressant, z.B. MPEG-4 könnte auch ein richtiger Knaller werden.
Ich sehe CTT als langfristiges Investment, was natürlich nicht ausschließen soll, dass je nach Kursentwicklung auch Gewinne realisiert werden.
Gruß
tupper

[circuit]

Es gibt ja nur rund 6 Mio. Aktien. Lass die "nur" Mal 5 -10 Mio. pro Jahr aus den Lizenzen verdienen ( ist meine Schätzung in der untersten Range ), dann kannst du dir ausmalen, wohin der Kurs geht ! Also auch ich werde Gewinne mitnehmen....aber erst bei 20,-- bis 30,--........

[tupper]

Hi, circuit!
Momentan sehe ich den fairen Wert bei ca. 8 $, da ist aber noch nicht besonders viel Fantasie eingepreist.

[circuit]

Nun ja, die Chefs sehen auch wesentlich höhere Kurse ( die gleichen wie ich ? )

Der CEO hat heute 5.000 Stück zu 4,80 $ gekauft:

CTT - Insider Transactions as of 10/26/04 @ 12:49:30 PM. Total 14 Records. Prev Close: $4.51 Avg Vol(3m): 10,954 P/E: 9.72 EPS: 0.46

Buy(P) /
date Filed Date Company Symbol Insider Relationship Share Amt. Unit Price Total Proceeds Shares Owned Details
P 2004-10-26 2004-10-26 10:57:04 COMPETITIVE TECHNOLOGIES INC CTT NANO JOHN B CEO 5,000 $4.80 $24,022.00 9,480 view

[tupper]

Ein Schnellmerker ist das aber auch nicht, sonst hätte er zu 2$ oder spätestens zu 3$ gekauft.
Nun ja, hoffnungsvolle CEOs bestärken auch meine Zuversicht.
Bin mal gespannt, wie lange es dauert, bis der Wert bei uns Beachtung findet.

[circuit]

In habe diesen CEO als sehr besonnenen Menschen "kennengelernt".
Er wartete eben erst die Ergebnisse in den Verhandlungen mit Bayer & Co. ab. Hätte sich ja alles auch noch hinausziehen können......
Aber nun sind die Türen aufgestoßen und alle anderen werden ( müssen ) folgen !

[tupper]

Ich bin erst Mitte des Jahres auf CTT aufmerksam geworden und habe mich dann hier und auf der Homepage eingelesen. Mein Eindruck dabei war auch, dass die Unternehmens- führung trotz aller Probleme fair und seriös agiert hat.
Mit dem Hintergrund fühlt man sich bei seinem Investment noch wohler.

[circuit]

Und der Vizepräsident ist der nächste Insider-Käufer von heute ( bei 5.18 $ )


2004-10-27 2004-10-27 13:33:08 COMPETITIVE TECHNOLOGIES INC CTT FREED DONALD J officer (Executive Vice President & CTO) 2,000 $5.18 $10,359.00

[tupper]

Von welcher Seite hast du deine Infos kopiert?
Sagt dir der Name Samuel Fodale etwas? Die genauen Vorgänge um diesen Typen würden mich interessieren.
Der besitzt evtl. noch 70 000 CTT.

[circuit]

Fodale hat nur noch 8.300 Aktien, hatte aber tatsächlich Mal fast 100.000 Stück.

Viel wichtiger ist dies ( hier kommen vielleicht noch weitere Millionen auf " uns " zu ):

FAIRFIELD, Conn., Oct. 28 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) announced today that it is demanding arbitration with Palatin Technologies, Inc. (Amex: PTN - News) for material breach of the terms of its license agreement for the exclusive use of CTT`s underlying sexual dysfunction technology used in the development of PTN`s experimental treatment for male and female sexual dysfunction. The agreement provides for CTT to receive 20% of the full sublicense fee that Palatin receives, such as the recent $20 million license payment from King Pharmaceuticals (NYSE: KG - News). Under the license agreement, Palatin owes CTT $4 million, which was due by October 17, 2004.

[tupper]

Die neueste Meldung hab ich schon mitgekriegt.
Woher hast du nur die genauen Zahlen? Ich hab nur eine Bestandsmeldung vom Juni 04 gefunden (waren um die 100 000)und dann noch verschiedene Verkaufsmeldungen.
Was hat denn dieser Fodale damals genau gedreht?

[circuit]

Buy(P) /
Sell(S) P/S date Filed Date Company Symbol Insider Relationship Share Amt. Unit Price Total Proceeds Shares Owned Details

P 2004-10-27 2004-10-27 13:33:08 COMPETITIVE TECHNOLOGIES INC CTT FREED DONALD J officer (Executive Vice President & CTO) 2,000 $5.18 $10,359.00 3,000 view

P 2004-10-26 2004-10-26 10:57:04 COMPETITIVE TECHNOLOGIES INC CTT NANO JOHN B CEO 5,000 $4.80 $24,022.00 9,480 view

S 2004-08-19 2004-10-21 11:15:08 COMPETITIVE TECHNOLOGIES INC CTT FODALE SAMUEL M director 700 $3.82 $2,674.00 8,300 view

[tupper]

Sieht für Palatin aber sehr bedrohlich aus. Zahlen können sie anscheinend nicht und wenn die Lizenz weg ist, können sie den Laden erst recht zumachen.

[tupper]

Press Release Source: Palatin Technologies, Inc.


Palatin Technologies Responds To Competitive Technologies` Demand For Arbitration
Thursday October 28, 4:12 pm ET


CRANBURY, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN - News) today issued a response to an announcement earlier today by Competitive Technologies, Inc. (Amex: CTT - News; "CTT") that CTT is demanding arbitration with Palatin for material breach of the terms of its license agreement. This license agreement is for certain technology related to PT- 141, Palatin`s therapeutic drug candidate for the treatment of both male and female sexual dysfunction.
ADVERTISEMENT


Palatin acknowledges it has received a letter demanding arbitration from CTT and that a dispute exists between CTT and Palatin concerning the interpretation of this license agreement relating to amounts that may be owed to CTT thereunder. The license agreement provides for binding arbitration as the remedy for dispute resolution. Palatin does not believe that this matter has any potential material impact on Palatin`s strategic collaboration with King Pharmaceuticals to jointly develop and commercialize PT-141 or on any of its intellectual property rights regarding PT-141. Palatin disputes CTT`s assertions, including that Palatin committed a "deliberate and conscious breach" of the license agreement and that $4 million may be owed. Palatin asserts that there is no breach to the license agreement and that any amounts owed would be substantially and materially less than $4 million. Palatin intends to defend itself vigorously in the arbitration and assert all rights accorded it under the license agreement and at law. Additionally, the portion of CTT`s announcement relating to the purported inconsistency of Palatin`s SEC filings is materially misleading and Palatin intends to explore all other remedies available to it.

[circuit]

Kümmern wir uns nun wieder um unsere eigenen Stärken, das patentieren lassen:

Competitive Technologies Announces Patent For Nanotechnology Bone Biomaterial Issued
Monday November 1, 9:01 am ET


FAIRFIELD, Conn., Nov. 1 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) announced today that patent number 6,808,561 has been issued by the US Patent Office for Dr. Brian R. Genge`s nanotechnology bone biomaterial developed at the University of South Carolina (USC). CTT has an exclusive agreement with the University of South Carolina Research Foundation to license and commercialize the nanotechnology, an injectible calcium phosphate-based biomaterial. Dr. Genge is a research professor in the Department of Chemistry and Biochemistry at USC.
"The granting of this patent recognizes the unique qualities of Dr. Genge`s innovative nanoparticle biomaterial technology," said Suzanne N. B. Alent, CTT`s VP Marketing and Business Development. "CTT has an agreement with a major dental products company to research the manufacture and use of this nanotechnology for dental applications. We will continue to aggressively market this superior technology for all aspects of its capabilities."

In addition to its use in the dental field, the patented nanotechnology can also be applied to a variety of human orthopedic procedures, especially related to the spine and craniofacial reconstruction, as well as veterinary uses. The bone biomaterial technology is an easily flowable, moldable paste that conforms to and interdigitates with the host bone. It rapidly hardens itself in vivo, forming a solid bone-like structure capable of stabilizing fractured bone within 15 minutes and supports the growth of cartilage and bone cells. The technology has superior compressive strength making it suitable for weight and non-weight bearing bones, and is both machinable and drillable.

John B. Nano, CTT`s President and CEO said, "CTT is proud to continue its successful relationship with USC and Dr. Genge. We are building and renewing our strong, global alliances with universities, companies and individual inventors. Bone biomaterial is just one of the exciting technologies in CTT`s innovative portfolio. We are actively marketing and commercializing several technologies, including homocysteine assays, video compression and decoding technology, sexual dysfunction treatment, sunless tanning application, silicon carbide wafer testing, encryption technology, EZSpeech(TM) language-mastering software, an anti-cancer compound and the Therapik® device."

[tupper]

Die Zahlen für das Geschäftsjahr 03/04 sind auch da:
EAT 3 Mio = 0,46/share.

[tupper]

Fodale hat seine letzten 8300 jetzt auch verscherbelt.
Dann kann`s ja weiter aufwärts gehen - irgendwann.

[circuit]

Ob das der alleinige Grund für diese Bewegung ist :

[circuit]

Es gibt keine ( uns bekannten ) Gründe, weshalb nach einem Test der 6,50 $ heute zum Schluß "technische" Gewinnmitnahmen angesagt sind/waren.

[circuit]

heute bereits kurzzeitig über 8.00 Da werden die anstehenden news aber " bombastisch " sein.

[circuit]

wenn jemand hierauf etwas gibt, Kursziel 17,00 $:

[circuit]

und weitere 13 % rauf, bei diesen heutigen news nicht die Obergrenze:

Competitive Technologies Reports Increased Profits for First Quarter Fiscal 2005
Monday December 13, 9:15 am ET


FAIRFIELD, Conn., Dec. 13 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) today announced profitable results for its fiscal first quarter for the three months ended October 31, 2004.
Revenues for first quarter of fiscal 2005 increased to $2.4 million compared with $1.4 million for first quarter of fiscal 2004. CTT`s net income for first quarter of fiscal 2005 was $1.0 million, $0.14 per share, compared with the net income for first quarter of fiscal 2004 of $0.3 million, $0.06 per share.

"Our first quarter results reflect the continued profitability we achieved in 2004 as well as a strong revenue stream," said John B. Nano, CTT`s President and CEO. "Revenues are up for first quarter fiscal 2005 versus 2004, including a substantial increase in royalties collected for past and current homocysteine assays and the stock dividend from MelanoTan Corporation. Our aggressive licensing program for the patented homocysteine assay will further strengthen our recurring revenue as we proceed through fiscal 2005. Our financial strength, driven by profits, continues to increase and shareholders` interest is now at $6.2 million."

"CTT continues to leverage near term opportunities while executing our longer term strategy for sustained growth," stated Mr. Nano. "We are proactively marketing our portfolio of innovative technologies including the homocysteine assay, video compression and decoding technology, the sexual dysfunction therapeutic, the sunless tanning technology, the nanotechnology bone biomaterial, silicon carbide wafer testing, encryption technology, an anti-cancer compound and the Therapik® medical device. With the most experienced management team in the company`s history we are exploiting our technology licensing market opportunities to build profitable recurring revenue streams that will drive shareholder value."

[circuit]

und sie sprudeln immer stärker ........die Lizenzeinnahmen:

Competitive Technologies Licenses Homocysteine Patent to Abbott
Thursday December 16, 9:02 am ET
Abbott Homocysteine Assays Carry Pass-Through License to Customers


FAIRFIELD, Conn., and ABBOTT PARK, Ill., Dec. 16 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) and Abbott (NYSE: ABT - News) announced today that a homocysteine patent license has been granted to Abbott under CTT`s U.S. Patent Number 4,940,658 and its foreign counterparts relating to homocysteine medical tests.
Under terms of the agreement, Abbott is granted a license to the CTT technology and will pay royalties on sales of Abbott homocysteine assays. Abbott`s homocysteine assay customers will be covered by the Abbott license from CTT. Abbott customers such as hospital and commercial laboratories that have separate homocysteine licenses from CTT will be relieved of their obligation to pay royalties on reportable homocysteine results obtained using the Abbott assay by virtue of the royalty paid by Abbott to CTT.

The agreement between CTT and Abbott includes a release to Abbott`s customers of any obligation to pay royalties to CTT for homocysteine test results obtained using Abbott assays in the past. CTT has agreed not to pursue royalties from any current or future Abbott customer with respect to past homocysteine assay tests purchased from other diagnostic companies. CTT is pursuing such royalties directly from the supplier diagnostic companies and reserves its rights against these supplier diagnostics companies.

[circuit]

Jetzt haben wir es ja etwas genauer ( und immer daran denken, es gibt nur knapp über 6 Mio. Aktien ):

On December 16, 2004, Competitive Technologies, Inc. ("CTT") announced that a license had been granted to Abbott Laboratories ("Abbott") under CTT`s U.S. Patent Number 4,940,658 for homocysteine assays. The granting of the license settled previously filed litigation between CTT and Abbott.

Pursuant to the license Abbott will pay a license fee and royalties on sales of Abbott homocysteine assays. The license will relieve Abbott customers from their obligation to pay royalties on results obtained using the Abbott assay by virtue of the royalty paid by Abbott to CTT. CTT`s share of the license fee (that will be paid in January 2005) will be $5.2 million. The license also releases Abbott`s customers of any obligation to pay royalties to CTT for homocysteine test results obtained using Abbott assays in the past, but does not entitle them to any refund of any royalties previously paid to CTT.

[tecdaexchen]

http://www.4investors.de/php_fe/index.php?sektion=topstory&I…

[circuit]

Competitive Technologies Highlights Double-Digit Growth Plan at Annual Meeting
Friday January 14, 10:30 am ET


FAIRFIELD, Conn., Jan. 14 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) held its annual meeting today at the American Stock Exchange in New York City. Richard E. Carver, CTT`s Chairman of the Board, and John B. Nano, President and CEO described the key aspects of the 2005 business plan which is expected to lead to double-digit growth in revenue and net income when compared to fiscal 2004 financial results. The full slide presentation is available on the Investors page at CTT`s website: http://www.competitivetech.net .
"The CTT business team is actively fulfilling its commitment of growth and achieving our strategic vision," said Mr. Carver. "Shareholders are beginning to realize value from their investment in CTT as the market recognizes the outstanding work being done at the company. The stock price for 2004 closed at $11.10, an improvement of 345.8% over the $2.49 closing at year-end 2003. We are proud to have the two new members elected to our Board, Drs. Maria-Luisa Maccecchini who brings to CTT a strong background in the important biotech industry and Donald J. Freed, who is currently the Executive Vice President and Chief Technology Officer at CTT. We also wish to thank Samuel M. Fodale for his past service to the company as he steps down from the Board."

Mr. Nano said, "As we continue to successfully implement our business plan, we expect fiscal 2005 to be even stronger than the exciting and profitable year we achieved in fiscal 2004. Our objective is double-digit growth in revenue and net income for fiscal 2005 ending July 31, 2005. I believe that CTT`s stock is trading at a very low p/e considering our trailing four quarters of earnings of $0.55 per share."

"We are building a strong, recurring revenue stream, successfully capitalizing on the technology and business expertise of our commercialization team, and are well positioned in a global licensing market that demands the dynamic technologies that are in our portfolio," continued Mr. Nano. "We are expanding our portfolio with quality, innovative technologies including the just-announced RFID tracking technology, the homocysteine assay, where we recently signed new royalty and license fee agreements, MPEG-4 video compression and decoding technology, where we recently incorporated a second patent into the License Pool, silicon carbide wafer testing, a sexual dysfunction therapeutic, encryption technology, a sunless tanning technology, a nanotechnology bone biomaterial, an anticancer compound and the Therapik® medical device. Our plan is to continue to leverage near-term opportunities while executing our longer-term strategies for sustained growth and increased shareholder value."

[circuit]

Und wieder neue Höchststände bei steigenden Umsätzen. Die gehandelten Blocks, sowie eine derzeitig Kauforder von 25.000 Stck. zu 11.95 $ ( noch im Markt ) lassen den jetzigen -späten- Einstieg von Spezialfonds vermuten. Die nächsten Zahlen Mitte Märze werden uns wohl weiter Richtung 20.00 $ laufen lassen:

[circuit]

Gibt es da etwa Ähnlichkeiten ( fundamental gesehen )?

[mlolo]

hallo leute

[mlolo]

ich interessiere mich sehr für competitive!
kann mir jemand sagen, wie ich an kennzahlen des unternehmens herankomme? bisher habe ich keine gefunden

[ara723]

Hallo,

Wertpapierkenn-Nr. ist klar: 860736,
auf www.pcquote.com US-Kürzel "ctt"

Gruß ara723

[circuit]

Kommt jetzt die zweite Welle ?

[circuit]

Das war wirklich eine Welle ! Solche Bewegungen sollen aber gesund sein.

[circuit]

Spät, aber noch nicht zu spät kommen nun auch die ersten US Empfehlungen. Es werden somit Kurse von knapp 30.00 erwartet:

Business Wire - February 04, 2005 06:00

CHICAGO, Feb 4, 2005 (BUSINESS WIRE) -- Dennis Slothower, editor of Stealth Stocks newsletter, says that sometimes investors win by doing nothing. Find out why this expert is staying defensive and how he is setting up for a sharp rally that could come at anytime. Then read about Stellent,

Inc. (NASDAQ:STEL),

Competitive Technologies, Inc. (AMEX:CTT)

A D A M, Inc. (NASDAQ:ADAM),

Abercrombie & Fitch Co. (NYSE:ANF), and Walgreen Co. (NYSE:WAG).
Highlights from the February 2nd Featured Expert column by Dennis Slothower includes:

Many times in the investing game, the big money is made by sitting on the sidelines. Slothower has started to position his portfolios into a defensive posture as we enter February. He is looking at a stock market that is deeply oversold, suggesting that a sharp rally can develop anytime. Bearish sentiment has reached levels that in the past have marked important bottoms, so we are setting up nicely for a run to the upside. Slothower`s analysis tells him that a sharp rally for stocks will begin once crude oil breaks down. Until he sees that, he can`t tell you that we are out of the woods just yet.

STOCKS THAT COULD DOUBLE IN A YEAR

Stellent, Inc. (NASDAQ:STEL) is a global provider of content management software solutions that enable fast implementations and generate quick, broad user adoption. For the six months ended 9/30/04, total revenues rose 41% to $50.6 million.

Competitive Technologies, Inc. (AMEX:CTT) provides technology transfer, selling and licensing services focused on the technology needs of its customers to match those requirements with commercially viable technology solutions. For the three months ended 10/31/04, revenues increased 78% to $2.4 million. Net income totaled $968,000, up from $345,000.

[circuit]

Nachdem Einige bestimmt noch immer und seit 2,00 US $ mit dabei sind, musste ich einfach Mal wieder den CTT Thread hochziehen.

Den Thread über einen der besten ( der beste ? ) Werte in diesem Board ..... und auch nach diesen Meldungen:

FAIRFIELD, Conn., March 14 /PRNewswire-FirstCall/ -- Competitive Technologies, Inc. (Amex: CTT - News) today announced record revenue and profits for the three and six months ended January 31, 2005.

Revenues for first half of fiscal 2005 nearly quadrupled to $9.2 million compared with $2.4 million for the first half of fiscal 2004. Revenues for the second quarter of fiscal 2005 increased to $6.8 million from $1.0 million in the second quarter of fiscal 2004. Revenues for the first half of fiscal 2005 include $7.0 million from royalties of the homocysteine assay technology.

CTT`s net income for first half of fiscal 2005 was $4.9 million, compared with the net income for first half of fiscal 2004 of $0.4 million, an improvement of $4.5 million. The net income of $4.0 million for second quarter of fiscal 2005 compares to a net income of $0.1 million in second quarter of fiscal 2004. CTT continues to benefit from its historic accumulated tax loss carryforwards.

"We continue to report strong profitable revenue growth," said John B. Nano, CTT`s President and CEO. "Revenues are up substantially for the quarter and the six months versus last year. These revenues include major increases in royalties collected for homocysteine assays and one-time up-front license payments. Our aggressive licensing program for the patented homocysteine assay will further strengthen our recurring revenue, we believe, as we proceed through fiscal 2005. Driven by strong profits, our $11.0 million working capital confirms our financial strength, and our shareholders` interest is now at $11.3 million versus $1.7 million at the end of January 2004."

"Our plan is to continue to leverage near-term opportunities while executing our longer-term strategies for sustained growth and increased shareholder value. We expect full year fiscal 2005 financial results will vary quarter to quarter and to be even stronger than the exciting and profitable results we achieved in fiscal 2004. Our objective is double-digit growth in revenue and net income for fiscal 2005 ending July 31, 2005. We expect to build a strong, recurring revenue stream, successfully capitalizing on the technology and business expertise of our commercialization team, and believe we are well positioned in a global licensing market that demands the dynamic technologies that are in our portfolio," continued Mr. Nano. "We are expanding our portfolio of quality, innovative technologies including the recently announced RFID tracking technology, the homocysteine assay, MPEG-4 video compression and decoding technology, where we recently incorporated a second patent into the license pool, a sexual dysfunction therapeutic, encryption technology, a sunless tanning technology, a nanotechnology bone biomaterial, an anticancer compound and the Therapik® medical device. We expect to successfully implement our business plan for building year by year profitable recurring revenue and shareholder value."

[ara723]

...we love it...

[mlolo]

@all kann mir mal jeman sagen, was da schon wieder los ist?

[ara723]

...vielleicht hängt es mit den am Freitag veröffentlichten
Zahlen zusammen.....siehe www.pcquote.com Kürzel "ctt"
news .....

[ara723]

Jun 15, 2005 (M2 EQUITYBITES via COMTEX) --
Competitive Technologies, Inc. (AMEX:CTT), a full service technology transfer and licensing provider, has announced that Dr. Donald J. Freed, the company`s Executive Vice President and Chief Technology Officer, has been appointed by the Board of Directors to serve as interim President and Chief Executive Officer effective immediately.

Freed replaces John B. Nano, who has ceased to serve in the positions of President and COO. The company said it anticipates that Nano will continue to be employed by the company on a consultancy basis.

[ara723]

Jun 15, 2005 (M2 EQUITYBITES via COMTEX) --
Competitive Technologies, Inc. (AMEX:CTT), a full service technology transfer and licensing provider, has announced its results for the third quarter and nine months ended 30 April 2005.

Revenues for the third quarter were USD2.5m compared to USD4.2m for the third quarter of fiscal 2004. Net income for the quarter was USD0.4m, down from a net income of USD2.7m in the third quarter a year ago.

Revenues for the first nine months of fiscal 2005 increased 79% to USD11.7m compared with USD6.6m for the first nine months of last year. Net income for the first nine months was USD5.3m, an improvement of USD2.2m from the net income for the first nine months of fiscal 2004 of USD3.1m.

[ara723]

...ich weiss nicht ob ich weinen oder lachen soll...

[circuit]

Lachen wegen den weiterhin guten Aussichten ... aber auch einige wenige Tränen vergießen für die unerwartete ( kurzfristig schädliche ) Personaldiskussion / Personalentscheidung die aber für die Zukunft des Unternehmens m.E. unbedeutend ist. Um 8.00 $ jederzeit ein Kauf für mich.

[ara723]

Competitive Technologies Announces Notice of Lawsuit by Former CEO

FAIRFIELD, Conn., Aug 15, 2005 (CCNMatthews via COMTEX) --
Competitive Technologies, Inc. (AMEX: CTT) announced today that on August 10, 2005, the Company received notice that John B. Nano, its former President and Chief Executive Officer had commenced suit in the Superior Court in the Judicial District of Stamford Connecticut seeking the pre-judgment remedy of attachment. Mr. Nano`s suit seeks to attach one of the Company`s bank accounts in the amount of $1.4 million to preserve his ability to collect should he succeed on his claims. In this suit, Mr. Nano alleges that CTT breached his employment contract because it denied him certain severance benefits when it terminated him on June 14, 2005. Mr. Nano also claims, in the alternative, that CTT violated a proposed but unexecuted and undelivered separation agreement and general release which it sought to negotiate with him at the time of his departure. According to his lawsuit, Mr. Nano claims that CTT withdrew the agreement after he communicated his acceptance to the Chairman of CTT`s Board of Directors. The Company denies the allegations of the suit and intends to vigorously defend it and oppose Mr. Nano`s application for a prejudgment remedy.

Dr. Donald J. Freed, the President and Chief Executive Officer of the Company commented, "We are quite disappointed that Mr. Nano has initiated this totally unwarranted action and intend to vigorously defend the interests of the Company and our stockholders. As we have repeatedly informed Mr. Nano and his attorneys, the Company to date has honored and has every intention to continue to honor all applicable provisions of Mr. Nano`s employment agreement, and expects Mr. Nano to do likewise."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT`s website: www.competitivetech.net

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on October 29, 2004, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Strategic IR, Inc.
Johnnie D. Johnson, 212-754-6565
[e-mail]
212-754-4333 (FAX)
[e-mail]
NEWS RELEASE TRANSMITTED BY CCNMatthews

[ara723]

Stocks >> NEWS


Competitive Technologies Reviews Strategic Directions; Announces Earnings Call to Discuss FY 2005 Results, and Personnel Changes

FAIRFIELD, Conn., Aug 15, 2005 (CCNMatthews via COMTEX) --
Competitive Technologies, Inc. (AMEX: CTT) announced today that as a result of its recently held Strategic Planning meeting with its Board of Directors, it has created a new strategic vision for the company with the main goal "to be recognized as the leader for licensing technology, commercializing technology, and transferring technology" as a part of focusing on long term profitable growth. One of the first steps approved by the Board of Directors was the filling of a number of new positions.

New Strategic Directions

The Company is directing its strategy to executing operations in an unambiguous, consistent and transparent manner to increase recurring revenue and profit. The need for a more focused strategic vision and implementation plan is a critical part of achieving that goal. Mr. Richard E. Carver, the Board Chairman, emphasized in a June press release that CTT needed to build for the future in a strategic manner that will produce increased shareholder value over the long term. We are clearly committed to using all of our resources to achieve that goal, with a focus on securing more technologies and recurring revenues by expanding our reach, both on the academic side and in industry.

Dr. Freed, CTT`s President and Chief Executive Officer stated, "I am pleased to announce the first ever earnings call in the Company`s history. We will discuss our fiscal year 2005 results, and our new strategic vision for the Company. We welcome all shareholders to participate in what will become a recurring communications activity." The specific date will be announced, but it will be shortly after our annual earnings release.

Personnel Changes

Dr. Michael Kiley is now Executive Vice President and Chief Technology Officer. Dr. Kiley joined Competitive Technologies in 2004 and his focus has been on CTT`s strategic planning process, RFID technology and University business development. Prior to joining CTT, he had over 14 years of operational U.S. Navy flying experience and 10 years of Navy program management experience, the majority of which was at the Office of Naval Research.

Aris D. Despo is now Senior Vice President, Life Sciences. Mr. Despo is responsible for identifying innovative medical/life science technologies, developing commercialization strategies, and managing relationships with universities and industry. He has over 20 years of executive level leadership in the chemical industry. Mr. Despo has been instrumental in managing CTT`s successful homocysteine licensing program.

Suzanne N. B. Alent has been appointed to the position of Chief Marketing and Corporate Communications Officer. She brings a strong background in global sales and marketing for technology companies, specializing in networking, hardware, software, computer telephony and information communication. In this newly created position, Ms. Alent will be responsible for all corporate marketing functions and corporate communications. Expanding the focus in these areas is another critical feature of the implementation of CTT`s new strategic vision.

Dr. Roger G. Stricker has been engaged as a Senior Consultant, Physical Sciences. He brings over 18 years of experience in the area of Intellectual Property Licensing and Business Development to CTT. Prior to his association with CTT, Dr. Stricker was the Intellectual Property and Licensing Vice President of Lucent Technologies. His responsibilities included licensing the worldwide patent portfolio of Lucent Technologies and Bell Laboratories. Dr. Stricker will be fully engaged going forward in assisting CTT in all aspects of the implementation of the new strategic vision.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT`s website: www.competitivetech.net

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on October 29, 2004, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to:

Strategic IR, Inc.
Johnnie D. Johnson, 212-754-6565
[e-mail]
212-754-4333 (FAX)
or
Competitive Technologies, Inc.
[e-mail]
NEWS RELEASE TRANSMITTED BY CCNMatthews

[ara723]

Stocks >> NEWS


American Type Culture Collection and Competitive Technologies Partner to Provide Novel Escrow Services for Licensed Biological Materials

MANASSAS, Va., and FAIRFIELD, Conn., Aug 22, 2005 (CCNMatthews via COMTEX) --
American Type Culture Collection (ATCC(R)) and Competitive Technologies, Inc. (AMEX: CTT) announced today the launch of a new escrow service for biological materials that are the subject of license agreements. This relationship will combine ATCC`s expertise in managing the storage and distribution of biological materials with CTT`s technology commercialization expertise.

The escrow service is designed to assist technology companies and universities in protecting valuable biological materials, as well as associated information. The escrow service will assure organizations engaged in licensing activities that their biological materials will remain secure and available to the parties as necessary during the term of a license agreement.

Protecting the security of biological materials and associated data is critical to ensuring continued advances in research and development and applying new technologies in biomedicine and industry.

"ATCC is delighted to partner with CTT in providing this important service. License agreements involving biological materials require a mechanism for assuring the security and continued availability of these materials during the effective term of the agreement," said Dr. Jesus Soriano, ATCC`s VP Licensing, Contracts and Compliance. "CTT`s expertise in commercializing intellectual property assures that the escrow service fully supports all elements of a licensing agreement. The new escrow service offers established and start-up technology companies a complete technology management service for biological materials."

"ATCC`s extensive experience in cryopreservation and storage of biological materials provides the necessary assurance that deposits of these materials for escrow purposes are maintained under the highest standards of security, safety and confidentiality," according to Aris Despo, CTT`s Senior VP for Life Sciences. "We are excited to bring this new escrow service to CTT`s expanding relationships with industry and universities. Our alliance with ATCC is part of our technology commercialization strategy to deliver value-added services to generate recurring revenue and increase shareholder value."

About American Type Culture Collection

Founded in 1925, ATCC is the world`s premier biological resource center. Its mission is to acquire, authenticate, preserve, produce, develop and share biological materials for the advancement of scientific knowledge. ATCC provides these core services in government, industry, education, health care and research laboratories around the world. Visit ATCC`s website: www.atcc.org.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT`s website: www.competitivetech.net.

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on October 29, 2004, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Strategic IR, Inc.
Johnnie D. Johnson, 212-754-6565
[e-mail]
212-754-4333 (FAX)
[e-mail]
NEWS RELEASE TRANSMITTED BY CCNMatthews